tiprankstipranks
Trending News
More News >
Boundless Bio Inc. (BOLD)
:BOLD
US Market
Advertisement

Boundless Bio Inc. (BOLD) AI Stock Analysis

Compare
31 Followers

Top Page

BOLD

Boundless Bio Inc.

(NASDAQ:BOLD)

Rating:40Underperform
Price Target:
Boundless Bio Inc. scores low due to its challenging financial situation with no revenue and high operational costs, despite some improvements in equity and liquidity. The technical analysis suggests possible short-term recovery potential, but the negative valuation metrics underscore the speculative nature of the stock. Investors should be cautious, as future gains depend heavily on successful product commercialization.
Positive Factors
Clinical Development
EcDNA-directed therapies could represent a breakthrough for drug-resistant tumors, with BBI-355 + BBI-825 offering a rational dual-node inhibition approach that could enhance clinical outcomes.
Financial Stability
The company reported $138 million in cash and cash equivalents, which they expect to provide runway into 2027, offering financial stability and risk mitigation.
Innovation
Boundless Bio's BBI-940 program is a first-in-class oral PROTAC degrader targeting a novel kinesin, potentially creating a competitive advantage in the market.
Negative Factors
Clinical Trial Setbacks
BOLD will be discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial due to a narrow therapeutic index, leading to a major development setback.
Investment Uncertainty
The validation of the ecDNA hypothesis with the ECHO diagnostic tool has been delayed, suggesting the investment thesis may remain uncertain until new assets are developed.
Stock Price Concerns
The company reported a reduction in price target from $5 to $4 per share, indicating potential concerns about stock performance.

Boundless Bio Inc. (BOLD) vs. SPDR S&P 500 ETF (SPY)

Boundless Bio Inc. Business Overview & Revenue Model

Company DescriptionBoundless Bio Inc. (BOLD) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in targeting extrachromosomal DNA (ecDNA) in cancer cells, aiming to address genomic amplification and improve treatment outcomes. Boundless Bio operates within the biopharmaceutical sector, leveraging cutting-edge research to create products that can potentially transform cancer care.
How the Company Makes MoneyBoundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary
Boundless Bio Inc. is facing significant financial challenges typical of a biotechnology start-up, with no revenue and high operational costs leading to continued losses. While there are improvements in equity and liquidity, the company heavily relies on external financing for operations. Future stability depends on successful product commercialization and operational efficiency improvements.
Income Statement
10
Very Negative
Boundless Bio Inc. has consistently reported zero revenue over the past years, indicating no sales or commercialized products. The net income has been negative, showing persistent losses, with net losses increasing year-over-year. The negative EBIT and EBITDA margins further highlight operational challenges and high costs relative to non-existent revenues.
Balance Sheet
40
Negative
The company has shown improvement in its equity position, moving from negative equity to a positive equity situation, which indicates better financial stability. However, the debt-to-equity ratio improvement is due to increasing equity rather than reducing liabilities. The company's cash and short-term investments have increased, providing liquidity, but liabilities remain substantial.
Cash Flow
30
Negative
Operating cash flow remains negative, reflecting the company's inability to generate cash from its core operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. However, significant financing activities suggest reliance on external funding to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2018
Income Statement
Total Revenue1.06M0.000.000.000.000.00
Gross Profit-368.00K-1.09M-957.00K-942.00K-682.00K0.00
EBITDA-61.23M-64.28M-48.48M-45.53M-24.62M-121.36M
Net Income-64.39M-65.36M-49.43M-45.90M-25.21M-128.82M
Balance Sheet
Total Assets179.45M206.41M129.89M76.83M113.72M472.56M
Cash, Cash Equivalents and Short-Term Investments127.15M152.11M120.75M66.72M73.03M414.31M
Total Debt49.51M47.63M2.19M5.18M377.00K7.07M
Total Liabilities56.76M55.77M256.98M158.53M151.91M29.80M
Stockholders Equity122.69M150.64M-127.08M-81.70M-38.19M442.75M
Cash Flow
Free Cash Flow-56.24M-63.38M-47.49M-40.66M-25.28M-119.59M
Operating Cash Flow-55.19M-60.84M-46.85M-39.60M-23.25M-107.98M
Investing Cash Flow38.30M-26.10M-38.26M16.13M-59.28M-185.05M
Financing Cash Flow217.00K89.82M97.90M126.00K105.53M398.46M

Boundless Bio Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.17
Price Trends
50DMA
1.13
Positive
100DMA
1.26
Negative
200DMA
1.82
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
51.85
Neutral
STOCH
70.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Positive. The current price of 1.17 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.13, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.85 is Neutral, neither overbought nor oversold. The STOCH value of 70.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLD.

Boundless Bio Inc. Risk Analysis

Boundless Bio Inc. disclosed 66 risk factors in its most recent earnings report. Boundless Bio Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Boundless Bio Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$6.52B1.65-10.19%6.24%14.92%-2.78%
49
Neutral
$44.49M-1205.58%203.23%13.57%
46
Neutral
$47.61M-53.78%-5.42%
45
Neutral
$60.53M-87.74%-60.16%
44
Neutral
$30.52M-78.25%248.62%26.22%
40
Underperform
$26.19M-42.65%-10.95%
39
Underperform
$62.65M-104.21%39.60%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BOLD
Boundless Bio Inc.
1.17
-2.76
-70.23%
PLUR
Pluri
5.68
0.39
7.37%
CLGN
Collplant Holdings
2.52
-2.58
-50.59%
ALXO
ALX Oncology Holdings
1.17
-1.40
-54.47%
ALGS
Aligos Therapeutics
10.20
-3.16
-23.65%
BRNS
Barinthus Biotherapeutics
1.18
-0.06
-4.84%

Boundless Bio Inc. Corporate Events

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Boundless Bio Shifts Focus and Restructures Leadership Team
Neutral
Dec 12, 2024

Boundless Bio announced significant updates to its ecDNA-directed therapy programs and leadership team. The company has decided not to advance its BBI-825 program due to complex treatment landscapes and is focusing resources on BBI-355, with initial clinical data expected in 2025, and the third ecDTx program, aiming for a development candidate by mid-2025. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo stepping in as interim CMO. These strategic decisions extend the company’s operational funding into 2027, demonstrating a commitment to advancing its therapeutic pipeline and addressing unmet oncogene-amplified cancer needs.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025